Search Result "PDUFA"
How Much Value Would a Treatment for Alzheimerâs Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy
Journal: Current Alzheimer Research
Volume: 17 Issue: 9 Year: 2020 Page: 819-822
Author(s): Hankyung Jun,Sang K. Cho,Elmar R. Aliyev,Soeren Mattke,Sze-Chuan Suen
Drug Withdrawals in the United States: A Systematic Review of the Evidence and Analysis of Trends
Journal: Current Drug Safety
Volume: 2 Issue: 3 Year: 2007 Page: 177-185
Author(s): Amalia M. Issa, Kathryn A. Phillips, Stephanie Van Bebber, Hima G. Nidamarthy, Karen E. Lasser, Jennifer S. Haas, Brian K. Alldredge, Robert M. Wachter, David W. Bates
Development of Tamper Deterrent Formulations: State of the Pharmaceutical Industry
Journal: Current Drug Abuse Reviews
Volume: 3 Issue: 3 Year: 2010 Page: 139-146
Author(s): Ehab Hamed, Derek Moe
The Practicing Clinician and Regulatory Safety Concerns
Journal: Current Drug Safety
Volume: 8 Issue: 1 Year: 2013 Page: 17-24
Author(s): R.G. McAllister, Timothy Franson, Carl N. Kraus
Targeting BLyS in Systemic Lupus Erythematosus
Journal: Recent Patents on Inflammation & Allergy Drug Discovery
Volume: 6 Issue: 2 Year: 2012 Page: 91-96
Author(s): Yaoyang Liu,Antonio La Cava
Membrane Interacting Peptides: A Review
Journal: Current Protein & Peptide Science
Volume: 17 Issue: 8 Year: 2016 Page: 827-841
Author(s): Alvaro I. Herrera,John M. Tomich,Om Prakash
The Regulation of Pharmacogenomics-based Drugs and Policy Making
Journal: Current Topics in Medicinal Chemistry
Volume: 4 Issue: 1 Year: 2004 Page: 1453-1458
Author(s): Amalia M. Issa
Recent Patents and Regulatory Aspects on Ophthalmic Drug Delivery Systems
Ebook: Treatise on Ocular Drug Delivery
Volume: 1 Year: 2013
Author(s): Soumyajit Majumdar,Ketan Hippalgaonkar,Tushar Hingorani,Walter G. Chambliss
Doi: 10.2174/9781608051755113010012
Strategies to Prolong the Useful Life of Existing Antibiotics and Help Overcoming the Antibiotic Resistance Crisis
Ebook: Frontiers in Clinical Drug Research: Anti-Infectives
Volume: 4 Year: 2017
Author(s): Marcelo E. Tolmasky
Doi: 10.2174/9781681084879117040003
Enasidenib: First Mutant IDH2 Inhibitor for the Treatment of Refractory and Relapsed Acute Myeloid Leukemia
Journal: Anti-Cancer Agents in Medicinal Chemistry
Volume: 18 Issue: 14 Year: 2018 Page: 1936-1951
Author(s): Raghav Dogra,Rohit Bhatia,Ravi Shankar,Parveen Bansal,Ravindra K. Rawal